merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>
<answer>significant safety risks such as brain swelling and bleeding</answer>
<question_number>2</question_number>
<answer>could discourage patients from enrolling in trials for alternative, potentially better drugs, slowing progress</answer>
<question_number>3</question_number>
<answer>no correlation between plaque removal and individual clinical response</answer>
<question_number>4</question_number>
<answer>heightens concerns about safety because of the higher incidence of brain swelling and bleeding</answer>
<question_number>5</question_number>
<answer>its higher price is offset by the expectation that treatment can stop once amyloid is cleared, reducing overall cost</answer>
<question_number>6</question_number>
<answer>may deter patients from joining other clinical trials</answer>
<question_number>7</question_number>
<answer>monthly dosing and the option to stop after amyloid clearance lessen treatment burden versus biâ€‘weekly Leqembi</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>patients with intermediate (lower) tau levels benefited more than those with high tau levels</answer>
